Department of Gastroenterological Surgery and Pediatric Surgery, Gifu University Graduate School of Medicine, Gifu, Japan.
Department of Pathology and Translational Research, Gifu University Graduate School of Medicine, Gifu, Japan; Center for One Medicine Innovative Translational Research, COMIT, Gifu University, Gifu, Japan.
Pathol Res Pract. 2024 Nov;263:155610. doi: 10.1016/j.prp.2024.155610. Epub 2024 Sep 25.
The high mortality rate of colorectal cancer (CRC) highlights the need for new treatment strategies; however, the venous invasion mechanisms in tumor endothelial cells within CRC remain unexplored. Therefore, we investigated the clinicopathological features of SRY-box transcription factor 17 (SOX17) in CRC. Immunohistochemical staining was performed on 55 CRC tissue specimens using a SOX17-specific antibody, followed by Kaplan-Meier and Cox proportional hazards regression analyses. SOX17 immunoreactivity was detected in the endothelial cells of tumor-penetrating vessels in 35/55 CRC samples. Kaplan-Meier analysis indicated that patients with SOX17 immunoreactivity had favorable overall and progression-free survival (log-rank test, P = 0.03 and 0.02, respectively). Notably, tumor endothelial SOX17 immunoreactivity was associated with a favorable prognosis in patients with stage III or IV disease (OS, P = 0.0089; PFS, P = 0.0065). Cox proportional hazard regression analysis indicated that SOX17 immunoreactivity is an independent factor for predicting favorable overall and progression-free survival in CRC (P = 0.02 and 0.01, respectively). The present findings suggest that SOX17 expression in tumor endothelial cells is a potential indicator of favorable prognosis in patients with CRC.
结直肠癌（CRC）的高死亡率凸显了新治疗策略的必要性；然而，CRC 肿瘤内皮细胞中的静脉侵袭机制仍未得到探索。因此，我们研究了性别决定区 Y 框转录因子 17（SOX17）在 CRC 中的临床病理特征。使用 SOX17 特异性抗体对 55 例 CRC 组织标本进行免疫组织化学染色，随后进行 Kaplan-Meier 和 Cox 比例风险回归分析。在 35/55 例 CRC 样本中，检测到穿透肿瘤的血管内皮细胞中的 SOX17 免疫反应性。Kaplan-Meier 分析表明，SOX17 免疫反应性患者的总生存率和无进展生存率良好（对数秩检验，P=0.03 和 0.02）。值得注意的是，肿瘤内皮 SOX17 免疫反应性与 III 期或 IV 期疾病患者的良好预后相关（OS，P=0.0089；PFS，P=0.0065）。Cox 比例风险回归分析表明，SOX17 免疫反应性是 CRC 患者总生存率和无进展生存率良好的独立预测因素（P=0.02 和 0.01）。这些发现表明，肿瘤内皮细胞中 SOX17 的表达是 CRC 患者预后良好的潜在指标。
